INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 48m ago
HOUSE PTR7m ago
SEC 13F7m ago
ROBINHOOD CHAIN7m ago
SEC FORM 4/Tax withholdingVerified data

Miller Aine reported TBPH

SVP, DEV & HEAD OF IRE OFFICE · Theravance Biopharma, Inc. · Ordinary Shares

Side
F
Value
$125K
Shares
6,989
Price
$17.9
Executed
Nov 20, 2025
Disclosed
Nov 24, 2025
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Nov 20 executedNov 24, 2025 disclosed

TBPH · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
12/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+4 / 25

    $125K reported value · 3.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TBPH

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    32.7K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    22.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.6K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    96.7K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    205.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    13.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    24.3K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    150.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    21
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    93.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    37.5K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    223.9K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    107.8K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    108.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    124.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    89.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    6,009 sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    42.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    1
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$57K
    3,328 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002012524-25-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 20, 2025
    Published
    Nov 24, 2025
    Ingested by INSIDER
    Nov 5, 04:31 UTC
    Last re-read
    Nov 5, 04:31 UTC

    Extracted facts

    Filer
    Miller Aine
    Role
    SVP, DEV & HEAD OF IRE OFFICE
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    Theravance Biopharma, Inc.
    Ticker
    TBPH
    Shares
    6,989
    Price per share
    $17.9
    Value
    $125,103
    Execution date (reported)
    Nov 20, 2025
    Owned after transaction
    201.0K shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 6,989
    • Price: $17.9

    = $125,103

    What this establishes

    Miller Aine filed this Form 4 reporting a tax withholding of TBPH on Nov 20, 2025. It became public on Nov 24, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, DEV & HEAD OF IRE OFFICE
    Miller Ainecik:0002012524
    Issuer
    Theravance Biopharma, Inc.cik:0001583107

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.